[PDF][PDF] Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy
M Dowsett, I Sestak, E Lopez-Knowles… - Journal of Clinical …, 2013 - researchgate.net
Journal of Clinical Oncology, 2013•researchgate.net
Purpose Risk of distant recurrence (DR) among women with estrogen receptor (ER)–
positive early breast cancer is the major determinant of recommendations for or against
chemotherapy. It is frequently estimated using the Oncotype DX recurrence score (RS). The
PAM50 risk of recurrence (ROR) score provides an alternative approach, which also
identifies intrinsic subtypes.
positive early breast cancer is the major determinant of recommendations for or against
chemotherapy. It is frequently estimated using the Oncotype DX recurrence score (RS). The
PAM50 risk of recurrence (ROR) score provides an alternative approach, which also
identifies intrinsic subtypes.
Purpose
Risk of distant recurrence (DR) among women with estrogen receptor (ER)–positive early breast cancer is the major determinant of recommendations for or against chemotherapy. It is frequently estimated using the Oncotype DX recurrence score (RS). The PAM50 risk of recurrence (ROR) score provides an alternative approach, which also identifies intrinsic subtypes.
researchgate.net
